Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes

Background: Unfractionated heparin (UFH) has been in clinical use for more than half a century. Monitoring UFH treatments is mandatory due to large inter- and intra-individual variations in its anticoagulant activity, with a risk of thrombosis in case of under-dosing and a risk of hemorrhage in case...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2019-11, Vol.134 (Supplement_1), p.3403-3403
Hauptverfasser: Appert-Flory, Anny, Fischer, Florence, Jambou, Didier, Buvat, Sylvain, Mahagne, Marie-Helene, Toulon, Pierre
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Unfractionated heparin (UFH) has been in clinical use for more than half a century. Monitoring UFH treatments is mandatory due to large inter- and intra-individual variations in its anticoagulant activity, with a risk of thrombosis in case of under-dosing and a risk of hemorrhage in case of over-dosing. Laboratory monitoring of UFH treatments is usually based on the prolongation of activated partial thromboplastin time (aPTT), or on the measurement of plasma anti-Xa activity. As UFH present in the patient's blood sample could be neutralized by platelet factor 4 (PF4) released by in-vitro activated platelets, it is recommended to perform the tests aimed at evaluating its anticoagulant activity as soon as possible after blood collection. Actually, the current guidelines recommend a maximum delay of 2 hours between blood sampling and testing for anti-Xa activity or aPTT prescribed for monitoring treatments by UFH, when blood is collected into citrated tubes. As such a short delay could be an issue, particularly for multisite centres, we evaluated the potential impact of a longer delay on test results. Design of the study: For that purpose, 2 citrated evacuated tubes containing 0.109 M tri-Na citrate (1 vol./9 vol.) were collected from patients on UFH: one was centrifuged and tested within 1h after blood collection (T1h) and one was stored for 4h at room temperature (+22°C) before being centrifuged and immediately analyzed (T4h). Methods: Anti-Xa activity was evaluated using 2 reagents: Biophen Heparin LRT (Hyphen Biomed, Neuville-sur-Oise, France) and HemosIL Liquid Heparin (Instrumentation Laboratory, IL, Bedford, MA, USA). aPTT was evaluated using the HemosIL SynthASil reagent (IL). All assays were automated on an ACL TOP 700 CTS (IL). As the distributions of the data were not found to be normal, anti-Xa and aPTT results were expressed as the median values (with ranges), and comparison of test results obtained at T1h and T4h performed using the Wilcoxon test. Test results were also compared according to Bland-Altman. Results: A total of 123 paired tubes were investigated. Analytical comparison of anti-Xa activity demonstrated a significant decrease (p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2019-130533